Key facts
- Telesair’s last known valuation is $24.0M (Mar 2026).
- It has raised $25.9M across 2 recorded rounds; the latest was Seed Round ($3.0M) in Feb 2026.
- Notable investors include ShangBay Capital, Berkeley Catalyst Fund Management, Device of Tomorrow Capital, Honeywell Ventures, Launchpad — 7 tracked in total.
- Telesair has filed 1 Form D with the SEC, most recently Feb 2023 ($22.8M sold to 31 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Telesair
Funding rounds
2 roundsAbout Telesair
Developer of respiratory therapy devices designed for delivering high flow oxygen therapy. The company provides systems with integrated temperature control, regulated oxygen delivery, and consistent humidification, incorporates clinician-informed design and ventilation expertise, supports use across hospital and home environments, and enables healthcare providers to manage respiratory care with controlled airflow conditions and adaptable treatment settings.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2020
- Employees
- 31
- Website
- telesair.com/
- Ownership
- Privately Held (backing)
Telesair doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Telesair shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Telesair in its N-PORT filings yet. We sweep new filings monthly.